

**QUALIFICATION CERTIFICATE
PURSUANT TO NATIONAL INSTRUMENT 44-101**

To: Alberta Securities Commission – Principal Regulator
British Columbia Securities Commission
The Manitoba Securities Commission
Ontario Securities Commission
Autorité des marchés financiers
Financial and Consumer Affairs Authority of Saskatchewan
Financial and Consumer Services Commission - New Brunswick
Office of the Superintendent of Securities Service Newfoundland and Labrador
Nova Scotia Securities Commission
Office of the Superintendent of Securities – Prince Edward Island
Office of the Superintendent of Securities, Department of Justice,
Government of Northwest Territories
Nunavut Securities Office, Department of Justice, Government of Nunavut
Office of the Yukon Superintendent of Securities

**Re: Preliminary short form base-shelf prospectus dated April 29, 2022
(the “Preliminary Shelf Prospectus”)**

I, Iris Bincovich, the Chief Executive Officer of Innocan Pharma Corporation (the “**Issuer**”), confirm that the Issuer is filing a preliminary short form base shelf prospectus pursuant to National Instrument 44-101 – *Short Form Prospectus Distributions* (“NI 44-101”) and National Instrument 44-102 – *Shelf Distributions* (“NI 44-102”). I hereby certify as an officer of and on behalf of the Issuer and not in my personal capacity as follows:

1. This certificate is being delivered pursuant to Sections 2.1 and 4.1 of NI 44-101.
2. The Issuer is relying on the criteria set out in Section 2.2 of NI 44-101 in order to be qualified to file a prospectus in the form of a short form prospectus.
3. The Issuer satisfies all the following criteria set out in Section 2.2 of NI 44-101 and Section 2.2 of NI 44-102 (capitalized terms utilized hereafter have the meaning assigned thereto in NI 44-101 and NI 44-102):
 - (a) the Issuer is an electronic filer under National Instrument 13-101 – *System for Electronic Document Analysis and Retrieval (SEDAR)*;
 - (b) the Issuer is a reporting issuer in at least one jurisdiction of Canada;
 - (c) the Issuer has filed with the securities regulatory authority in each jurisdiction in which it is a reporting issuer all periodic and timely disclosure documents that it is required to have filed in that jurisdiction (i) under applicable securities legislation, (ii) pursuant to an order issued by the securities regulatory authority, or (iii) pursuant to an undertaking to the securities regulatory authority, as applicable;
 - (d) the Issuer has, in at least one jurisdiction in which it is a reporting issuer, (i) current annual financial statements, and (ii) a current annual information form; and
 - (e) the Issuer’s equity securities are listed and posted for trading on a short form eligible exchange, and the Issuer is not an issuer (i) whose operations have ceased, or (ii) whose principal asset is cash, cash equivalents, or its exchange listing.

4. All of the material incorporated by reference in the Preliminary Shelf Prospectus has been previously filed.

Dated: April 29, 2022

INNOCAN PHARMA CORPORATION

"Iris Bincovich"

Name: Iris Bincovich
Title: Chief Executive Officer